

CONFIDENTIAL
PROPOSED CLAIMS
FOR DISCUSSION PURPOSES ONLY

21. A pharmaceutical composition useful for treating Galactosialidosis comprising protective protein/cathepsin A (PPCA) and a pharmaceutically acceptable carrier, wherein said PPCA is produced in an insect cell culture and has a unique glycosylation pattern that includes exposed mannose residues.
comprises
22. The composition of claim 21 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.
23. The composition of claim 22 wherein said cells are *Spodoptera frugiperda* Sf9 cells.
24. The composition of claim 21 wherein said PPCA is produced in the insect cell culture using a baculovirus expression system.

Proposed claim 21 incorporates limitations suggested in the July 1 Office Action. Support for the limitation regarding the unique glycosylation pattern and exposed mannose residues can be found at page 14, lines 7-8 of the specification. Other limitations appear in existing claims.

Proposed dependent claims 22-24 correspond to pending claims 11-13.

? cancel the claims &
non-elected claims